Is tezepelumab more than just an anti-eosinophil drug?
- PMID: 34972684
- DOI: 10.1183/13993003.01700-2021
Is tezepelumab more than just an anti-eosinophil drug?
Conflict of interest statement
Conflict of interest: A. Adatia was supported by the Canadian Institutes of Health Research/Canadian Allergy, Asthma, and Immunology Foundation/AstraZeneca/Allergen NCE Emerging Scientist Award in Allergic Asthma. Conflict of interest: M. Wahab has nothing to disclose. Conflict of interest: I. Satia is currently supported by the E.J. Moran Campbell Early Career Award, Department of Medicine, McMaster Univesity and previously reports grants from the ERS (RESPIRE3 Marie Curie Award), BMA James Trust Award, North West Lung Centre Grant; personal fees and sponsorship to attend meetings from Merck MSD, Genentech, AstraZeneca and GSK, outside the submitted work.
Comment on
-
The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM).Eur Respir J. 2021 Dec 31;59(1):2101296. doi: 10.1183/13993003.01296-2021. Print 2022 Jan. Eur Respir J. 2021. PMID: 34049943 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical